SCHEMBL29567608

SCHEMBL29567608

CS(=O)(=O)NCc1ccc(-n2cc(-c3ccnc4[nH]cnc34)cn2)nc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 3/20 0.34
▸ JAK2 O60674 5/20 0.34
▸ JAK1 P23458 3/20 0.34
▸ JAK3 P52333 2/20 0.34
▸ AURKA O14965 2/20 0.33
▸ AURKB Q96GD4 2/20 0.33
▸ KDM4A O75164 1/20 0.33
▸ KDM4B O94953 1/20 0.33
▸ KDM5C P41229 1/20 0.33
▸ KDM5B Q9UGL1 1/20 0.33
▸ TYK2 P29597 1/20 0.33
▸ CLK2 P49760 3/20 0.32
▸ CLK3 P49761 3/20 0.32
▸ DYRK1A Q13627 3/20 0.32
▸ WNT1 P04628 2/20 0.32
▸ INCENP Q9NQS7 1/20 0.32
▸ TPX2 Q9ULW0 1/20 0.32
▸ TGFBR1 P36897 1/20 0.32
▸ RET P07949 3/20 0.32
▸ NAMPT P43490 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22736278 0.88 GRM4 (0.35) GRM4JAK2JAK1JAK3AURKA
SCHEMBL29567624 0.88 GRM4 (0.35) GRM4JAK2JAK1JAK3AURKA
SCHEMBL31158257 0.83 GRM4 (0.34) GRM4JAK2JAK1JAK3AURKA
SCHEMBL22735719 0.83 GRM4 (0.34) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480555 0.83 GRM4 (0.38) GRM4JAK2AURKAAURKBKDM4A
SCHEMBL22736280 0.83 GRM4 (0.38) GRM4JAK2AURKAAURKBKDM4A
SCHEMBL22736174 0.81 JAK2 (0.33) GRM4JAK2JAK1JAK3TYK2
SCHEMBL22736491 0.81 JAK2 (0.33) GRM4JAK2JAK1JAK3KDM4A
SCHEMBL29567204 0.81 JAK2 (0.33) GRM4JAK2JAK1JAK3KDM4A
SCHEMBL22736230 0.80 GRM4 (0.38) GRM4JAK2JAK1JAK3AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US claimed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP claimed
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US disclosed
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD. (IN) 2022-07-28 — — US disclosed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 JAK1, JAK2, JAK3 GRM4 2623/4885JAK2 2/4885JAK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback